IPO
Auris Medical Holding Ltd. provided a business update, including a review of recent clinical, regulatory and operational highlights and progress.
InflaRx reported financial and operating results for the first quarter ended March 31, 2019.
Medtronic plc announced financial results for its fiscal year and fourth quarter 2019, which ended April 26, 2019.
All Resolutions Proposed by the Company’s Management Approved
The company focuses on developing a novel class of drugs called Bicycles. Bicycles are fully synthetic short peptides constrained to form two loops—hence “bi” cycles—that stabilize their structural geometry.
Pharming Group N.V. announces that at its Annual General Meeting of shareholders, all proposals were approved.
Motif Bio plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the Company’s AGM held earlier the Company provided the following review of key aspects of its business and growth strategy.
Biotech company Athera announce the closing of new share issue, raising in total 55 million SEK from current major shareholders including Industrifonden and Östersjöstiftelsen, together with new shareholders from the Sciety network of investors.
Promore Pharma’s most important task is to develop new products aiming to improve the quality of life for patients with difficult-to-treat wounds and various types of scarring, primarily following surgery.
Auris Medical Holding Ltd. announced that it has received written notification from the Nasdaq Hearings Panel notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market.
PRESS RELEASES